Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 21Unknown 4Terminated 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Lymphoma 8Lymphoma, Follicular 7Leukemia 7Prostatic Neoplasms 4Leukemia, Lymphocytic, Chronic, B-Cell 4Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Glioblastoma 3Burkitt Lymphoma 3Astrocytoma 3Stomach Neoplasms 2Rectal Neoplasms 2Neoplasms, Plasma Cell 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Chronic-Phase 2Colonic Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Brain Neoplasms 2Wilms Tumor 1Urinary Bladder Neoplasms 1

Interventions

Dexamethasone 112Bortezomib 61Lenalidomide 49Cyclophosphamide 49Calcium Dobesilate 43pomalidomide 32Melphalan 31fludarabine 25Filgrastim 25carfilzomib 22fludarabine phosphate 21daratumumab 20Granulocyte Colony-Stimulating Factor 16Whole-Body Irradiation 15Antilymphocyte Serum 15dexamethasone acetate 14Mycophenolic Acid 14Thalidomide 13Tacrolimus 13Cyclosporine 13Busulfan 13Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Radiotherapy 9Etoposide 9belantamab mafodotin 8Rituximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Multiple Myeloma × sargramostim × Clear all
NCT01174082 2018-06-01

Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant

M.D. Anderson Cancer Center

Phase 2 Terminated
2 enrolled 7 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00005987 2017-11-29

Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
87 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡